E.g. 427 highlights at ASGCT -important progress with his

• The data emphasizes the advantages of a single, non-replicative HSV-1 (NRHSV-1) vector with two transgenes with independent expression kinetics
• The vectors also show a high transduction rate of neurons in the CNS in very low doses and can be efficiently distributed to connected brain regions via a retrograde transfer
• Supports the growth of pipeline that use new vector attributes to cope with the challenges of genetic medicine on highly increasing pathologies

Paris, France, May 13, 2025 (Globe Newswire) -ZB 427 announced today, which highlights the leading role of the company in the development of non-replicating HSV-1 (NRHSV-1) vectal technology in neurology. The data will be presented at the 28th annual conference of the American Society of Cell and Gent Therapy (ASGCT) from May 13th to 17th, New Orleans.

In the first of two accepted posters, z. B. 427 A vector that contains two different transgenic, under the control of independent regulatory elements in various epigenetic regions of the HSV 1 genome. In vitro And In vivo Studies have shown that this unique vector technology enables the two transgenes to be expressed with different permanent patterns. In this case, the transgen, inserted outside the so -called latency area, showed a short expression period, while the transgen inserted in the latency region for the duration of the times tested was expressed stably.

“This innovative NRHSV-1 vector with a dual-point load, which enables the delivery of several transgenic with different expression dynamics in the same cell, offers a completely new approach to genetic medication of the future,” said Teddy Jégu, Ph.D. With several vector constructs for the provision of a single transgen, our eyesight, for example, to develop a single vector with the ability to delete genes in vivo, with temporary expression of gene-editing protein and the ability to replace a dominant disease of the long-term. “

A second poster will highlight the development of a NRHSV-1 vector, which is generally aimed at cortical neurons when administration in the striatum, which projects in this area. This vector derived from our Hermes platform expresses the Mgreenlantern -Reporter -under the control of the CAG promotor. When our vector was stereotactically injected into the striatum of mice, he showed high-ranking transgen expression in the cortical neurons of layer V. This is in contrast to previous academic experiments that show poor transgen expression with strongly defective HSV-1 vectors. In addition, it was found that cells that express mgreenlanters in the cortex are only neurons. Stable transgen expression levels were observed at least six weeks after administration. This opens up the way for a unique targeted bio distribution of therapeutic proteins in the brain in order to tackle a wide range of neurodegenerative diseases.

“We have made great progress in the further development of our new, non-replicative HSV-1 vector platform, which can be seen not only in the data presented at ASGCT, but also in the significant milestone, which was announced at the beginning of this year when we treated the first patient in our clinical study with EG110A in spincers who suffered from the dysfunction of EG110A, in Philippe Chambon, Md.

Poster details
Presentations will be carried out on May 13th at 6:00 p.m. to 7.30 p.m. CDT in Hall I2

873: New gene therapy vehicle for the expression of several transgenic with different expression kinetics
Presented by Justine Basset (Senior Scientist)

537: Long-term expression of transgen in targeted cortical neurons after inoculation in the mouse striatum of a non-replicative HSV-1 vector.
Presented by Julien Ratelade (preclinical manager)

Over 427
For example, 427 is leading worldwide in the non-replicating HSV-1 (NRHSV-1) vector technology in neurology. For example, 427 has started a phase 1/2 study with its candidate for genetic medicine, EG110A, in patients with neurogenic detrusor overactivity (neurogenic bladder) in connection with incontinence with neurogenic detrusor. This is the first human study of this type of vector that aims to aim at sensory neuron base diseases. EG110A is developed to remedy several severe bladder diseases, including the overactive bladder (OAB), and has the potential to be a significant improvement compared to existing therapies, which leads to better care for patients and lower costs for health systems.

Pinpoint -Neurotherapeutika provides the unique Hermes platform of the company to treat the prevailing diseases of the peripheral and the central nervous system. His vectors can achieve focal transduction in certain regions and then, thanks to the control of highly developed regulatory elements in targeted subgroups of neurons, achieve the selective expression of transgenes. With the proven clinical security and a possible repeated dosage, the large payload capacity of NRHSV-1 vectors enables a versatile DNA tax for more intelligent genetic medicine.

For more information:
Read our website at www.eg427.com

Follow us at www.linkedin.com/company/eg427/

Contacts:
E.g. 427
Philippe Chambon, MD, Ph.D.
Founder and CEO
pchambon@eg427.com

Global media relationships
Sophie Baumont
Rose piquant advice
Sophie.baumont@rosepiquante-consulting.com
+33 6 27 74 74 49